Personalis, Inc.PSNLNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Latest News

businesswire.com

Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of a new study in npj Precision Oncology highlighting the power of its ultrasensitive molecular residual disease (MRD) assay, NeXT Personal®, in monitoring immunotherapy response across a broad range of advanced cancers. The study, titled "Ultrasensitive ctDNA monitoring reveals early predictors of immunotherapy response in advanced cancer," wa.

businesswire.com

Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 11, 2026 at the Cliff Lodge in Snowbird, UT. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new par.

defenseworld.net

Personalis, Inc. (NASDAQ:PSNL) Given Average Rating of “Moderate Buy” by Analysts

Shares of Personalis, Inc. (NASDAQ: PSNL - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the eight ratings firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy

businesswire.com

Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the early access launch of Real-Time Variant Tracker, a powerful new option added to its ultrasensitive NeXT Personal molecular residual disease (MRD) test designed to detect small traces of circulating tumor DNA (ctDNA) in the blood that represent residual or recurrent cancer. Clinicians using the NeXT Personal MRD test will now be able to opt-in for additional reporting.

businesswire.com

Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported certain unaudited preliminary financial and operational results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter Strategic and Operational Highlights Secured Milestone Medicare Coverage: Received Medicare coverage approval for the surveillance of cancer recurrence in breast cancer patients, a key catalyst for clinical revenue and mar.

gurufocus.com

ARK Invest Boosts Gene-Editing Bets While Cutting Consumer Tech Exposure

Cathie Wood's ARK Invest is entering 2026 with a noticeably sharper bet on early-stage biotechnology, while selectively reducing exposure to consumer technology

defenseworld.net

Personalis, Inc. (NASDAQ:PSNL) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Personalis, Inc. (NASDAQ: PSNL - Get Free Report) have earned an average rating of "Moderate Buy" from the eight analysts that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating on the

defenseworld.net

Personalis, Inc. (NASDAQ:PSNL) Given Consensus Rating of “Moderate Buy” by Brokerages

Personalis, Inc. (NASDAQ: PSNL - Get Free Report) has received an average recommendation of "Moderate Buy" from the eight research firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have assigned a buy recommendation to the company. The

businesswire.com

Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of a new study in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR). The paper, titled "Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy," details results from Dr. Rodrigo Toledo and a leading team at the Vall d'Hebron Institute of Oncology (VHIO).

businesswire.com

New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of one of the largest and most comprehensive patient cohorts to date from the landmark TRACERx study, in the journal Cell. The study, titled "Longitudinal ultrasensitive ctDNA monitoring for high-resolution lung cancer risk prediction," demonstrates the clinical importance of ultrasensitive, tumor-informed molecular residual disease (MRD) testi.

defenseworld.net

Connor Clark & Lunn Investment Management Ltd. Purchases Shares of 68,679 Personalis, Inc. $PSNL

Connor Clark and Lunn Investment Management Ltd. acquired a new position in Personalis, Inc. (NASDAQ: PSNL) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 68,679 shares of the company's stock, valued at approximately $451,000. Connor Clark and Lunn Investment Management Ltd.

businesswire.com

Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at the Lotte New York Palace in New York, NY. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guidi.

businesswire.com

Personalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast Cancer

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced Medicare coverage of its ultrasensitive NeXT Personal® test for surveillance of cancer recurrence in breast cancer patients. This milestone marks an important step forward in cancer surveillance, offering a powerful tool for doctors and breast cancer patients. Medicare beneficiaries with stage II and III breast cancer, including the three major subtypes HR+/HE.

seekingalpha.com

Personalis, Inc. (PSNL) Q3 2025 Earnings Call Transcript

Personalis, Inc. ( PSNL ) Q3 2025 Earnings Call November 4, 2025 5:00 PM EST Company Participants Christopher Hall - President, CEO & Director Aaron Tachibana - CFO & COO Richard Chen - Executive VP of R&D and Chief Medical Officer Conference Call Participants Caroline Corner - Westwicke Partners, LLC Thomas Flaten - Lake Street Capital Markets, LLC, Research Division Mark Massaro - BTIG, LLC, Research Division Daniel Brennan - TD Cowen, Research Division Thomas VonDerVellen - Guggenheim Securities, LLC, Research Division Michael Matson - Needham & Company, LLC, Research Division John Wilkin - Craig-Hallum Capital Group LLC, Research Division Yu He - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good afternoon, and welcome to the Personalis Third Quarter 2025 Earnings Conference.

zacks.com

Personalis (PSNL) Reports Q3 Loss, Tops Revenue Estimates

Personalis (PSNL) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.64 per share a year ago.

businesswire.com

Personalis Reports Third Quarter 2025 Financial Results

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the third quarter ended September 30, 2025. The quarter was distinguished by significant operational momentum in its "Win-in-MRD" strategy, headlined by increasing clinical tests delivered and robust clinical evidence generation. Third Quarter 2025 and Recent Business Highlights Accelerated Clinical Adoption: Delivered 4,388 clinical tests.

businesswire.com

Personalis to Announce Third Quarter 2025 Financial Results

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its third quarter 2025 financial results on Tuesday, November 4, 2025. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for dom.

zacks.com

Personalis (PSNL) Moves 20.5% Higher: Will This Strength Last?

Personalis (PSNL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

businesswire.com

Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca phase 3 clinical trial in lung cancer (LAURA). The findings demonstrate that Personalis' highly sensitive molecular residual disease (MRD) test, NeXT Personal®, is a useful tool in assessing the maintenance treatment response post-CRT in patients with unresectable stage III, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC). The ne.

businesswire.com

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted, on September 15, 2025, a non-qualified stock option to purchase an aggregate of 440,000 shares of its common stock to Personalis' new Senior Vice President, Chief Information Officer under Personalis' 2020 Inducement Plan. The 2020 Inducement Plan is used exclusively for the grant of equity awa.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance